Quantum BioPharma contracts Thermo Fisher Scientific to support Phase 2 trial for MS therapy Lucid-MS

Quantum BioPharma (NASDAQ: QNTM) said it is partnering with Thermo Fisher Scientific's clinical research division to launch a Phase 2 clinical trial for its multiple sclerosis treatment, Lucid-MS. The companies signed a Study Start-Up Agreement following the therapy's recent FDA clearance; financial terms were not disclosed.

Detected & updated continuously · Source: Nebula